Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

2.

Combination chemotherapy for advanced bilharzial bladder carcinoma.

Khaled HM, Gad el-Mawla N, el-Said A, Hamza MR, Gaafar R, el-Attar I, Abu Rabia A, Magrath I.

Ann Oncol. 1996 Sep;7(7):751-4.

PMID:
8905036
3.

Use of ifosfamide in the management of breast cancer.

Gad-el-Mawla N.

Ann Oncol. 1992 Aug;3 Suppl 3:21-3. Review.

PMID:
1390313
4.

Prolonged disease-free survival in pediatric non-Hodgkin's lymphoma using ifosfamide-containing combination chemotherapy.

Gad-el-Mawla N, Hamza MR, Abdel-Hadi S, el-Tannir O, Hussein MH, el-Haddad A, Adde M, Magrath I.

Hematol Oncol. 1991 Jul-Oct;9(4-5):281-6.

PMID:
1743631
5.

A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder.

Gad el Mawla N, Mansour MA, Eissa S, Ali NM, Elattar I, Hamza MR, Khaled H, Habboubi N, Magrath I, Elsebai I.

Ann Oncol. 1991 Feb;2(2):137-40.

PMID:
2054316
6.

Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.

Gad-el-Mawla N, Hamza MR, Zikri ZK, Elserafi M, el-Khodari A, Khaled H, Gafaar R.

Cancer Chemother Pharmacol. 1990;26 Suppl:S85-6.

PMID:
2347057
7.

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.

Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, et al.

J Clin Oncol. 1989 Sep;7(9):1229-38.

PMID:
2671283
8.

Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen.

Gad-el-Mawla N, Hussein MH, Abdel-Hadi S, el-Taneer O, Adde M, Magrath I.

Cancer Chemother Pharmacol. 1989;24 Suppl 1:S20-3.

PMID:
2758567
9.

Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt.

Gad-el-Mawla N, Hamza MR, Zikri ZK, el-Serafi M, el-Khodary A, Khaled H, Abdel-Wareth A.

Acta Oncol. 1989;28(1):73-6.

PMID:
2706136
10.
11.

Ifosfamide in advanced pancreatic cancer. A 5-year experience.

Gad-el-Mawla N.

Cancer Chemother Pharmacol. 1986;18 Suppl 2:S55-6.

PMID:
3102092
12.

Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.

Rivkin SE, Glucksberg H, Foulkes M, Osborne CK, Tranum W, Gad-el-Mawla N, Constanzi J.

World J Surg. 1985 Oct;9(5):719-22. No abstract available.

PMID:
3840628
13.

Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study.

Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M.

Cancer. 1984 Nov 15;54(10):2248-56.

14.

Preoperative adjuvant chemotherapy in relatively advanced head and neck cancer.

Gad-El-Mawla N, Abul-Ela M, Mansour MA, Macdonald JS.

Am J Clin Oncol. 1984 Jun;7(3):195-8.

PMID:
6539564
15.

Hexamethylmelamine in advanced head and neck cancer. A phase II study.

Gad-El-Mawla N, Macdonald JS, Khaled H.

Am J Clin Oncol. 1984 Jun;7(3):205-8.

PMID:
6428214
16.

Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.

Gad-el-Mawla N, Ziegler JL, Hamza R, Elserafi M, Khaled H.

Cancer Treat Rep. 1984 May;68(5):793-4. No abstract available.

PMID:
6426792
17.

Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder.

Gad-el-Mawla N, Ziegler JL, Hamza R, Elserafi M, Khaled H.

Cancer Treat Rep. 1984 Feb;68(2):419-21. No abstract available.

PMID:
6697330
18.

Pediatric Hodgkin's disease in Egypt.

Gad-El-Mawla N, El-Deeb BB, Abu-Gabal A, Abdel-Hadi S, Hamza MR, Zikri ZK, Elsrafi M, El-Khoudary A, Elsaifi M, Aboul-Einein M, El-Bolkainy MN.

Cancer. 1983 Sep 15;52(6):1129-31.

19.

Phase II study of vindesine in patients with Hodgkin's disease, lymphoma, and breast cancer.

Gad-El-Mawla N, Hamza MR, El-Serafi M, El-Khoudary A, Aboul-Einein M, El-Demerdash S.

Cancer Treat Rep. 1983 Mar;67(3):316-7. No abstract available.

PMID:
6831481
20.

Analysis of human urine for mutagens associated with carcinoma of the bilharzial bladder by the Ames Salmonella plate assay.

Everson RB, Gad-El-Mawla NM, Attia MA, Chevlen EM, Thorgeirsson SS, Alexander LA, Flack PM, Staiano N, Ziegler JL.

Cancer. 1983 Feb 1;51(3):371-7.

Supplemental Content

Loading ...
Support Center